Reconstructed Adeno-Associated Virus with sPD-1 Induces Antitumor Immunity

Currently cancer gene therapy using recombinant DNA technology provides a new and promising treatment models aim to destruction the malignant growth (Qian et al., 2004; Xing et al., 2011). A variety of gene therapy-based anticancer strategies have been tested in animal tumor models, including selective activation of prodrugs, genetic immunotherapy, antiangiogenic actions and replacement of tumor suppressor genes (Sangro et al., 2002; Borghouts et al., 2005; Cao et al., 2010), successful of these approaches was depend on efficient gene transfer process, numerous gene transfer vectors have been developed, most of these approaches have used retroviral vector producer, naked DNA, oligodendromer DNA coatings, electroporation or adenoviral vectors (Qian et al., 2000; Cross et al., 2006). However, retroviral vector producers may be impractical for human use due to low titer of the vector, and the transfer of naked DNA is typically an inefficient, transient process; adenoviralmediated gene transfer is also complicated by transient